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Intervertebraldisc(IVD)degenerationisfrequent,appearingfromtheseconddecadeoflifeandprogressingwithage.Conservative
managementoftenfails,andpatientswithIVDdegenerationmayneedsurgicalintervention.Severaltreatmentstrategieshavebeen
proposed, although only surgical discectomy and arthrodesis have been proved to be predictably eﬀective. Biological strategies
aim to prevent and manage IVD degeneration, improving the function and anabolic and reparative capabilities of the nucleus
pulposus and annulus ﬁbrosus cells and inhibiting matrix degradation. At present, clinical applications are still in their infancy.
Further studies are required to clarify the role of growth factors and anticatabolic substances for prevention and management of
intervertebral disc degeneration.
1.Introduction
The physiological homeostasis of the various tissues of the
intervertebral disc (IVD) is regulated by the active mainte-
nance of the balance between the anabolism and catabolism
of IVD cells [1, 2]. This mechanism is maintained through
a complex coordination of a variety of substances and mole-
cules, including growth factors, enzymes, enzyme inhibitors
and cytokines, that act in a paracrine or/and autocrine
fashion [1, 2]. IVD degeneration usually begins from the
second decade of life, and progresses with aging [3]. The lack
of nutrients [4] and inappropriate mechanical loads [5]m a y
result in loss, alteration, and dysfunction of cell viability and
IVD properties [6, 7]. Medical conditions associated with
symptomatic IVD degeneration include IVD herniation,
radiculopathy, myelopathy, spinal stenosis, instability- and
low-back pain, and they represent the most common diag-
noses facing spine specialists [8–14]. The accepted treatment
for IVD degeneration consists discectomy with vertebral
fusion. New biological strategies have not yet been proven to
be eﬀective.
This review reports the state-of-the-art on the man-
agement of IVD degeneration using growth factors and
anticatabolic molecules.
2. Biology of the Intervertebral Disc
The IVD is constituted by three parts: the annnulus ﬁbrosus
(AF), the nucleus pulposus (NP), and the endplate (EP).
The IVD matrix is composed of an ordered framework
of macromolecules able to attract and hold water; the
most represented structural components are collagens and
proteoglycans [15]. Collagenous proteins are present in the
AF while proteoglycans are present in the NP. The function
of collagen is to provide form and tensile strength while
proteoglycans are responsible for tissue viscoelasticity, stiﬀ-
ness, and resistance to compression through their peculiar
interaction with water [6]. Only 20% of collagenous proteins2 Stem Cells International
are found in the central NP while a 50% of proteoglycans
are located in AF and NP, respectively [15]. The integrity of
the IVD is maintained by the balance between matrix syn-
thesis/appositionanddegradation.Integrityismaintainedby
a ﬁne balance of the activity of cytokines, growth factors,
enzymes, and enzyme inhibitors, in a paracrine or/and
autocrine fashion. Morphological and molecular changes
occur in the IVD with aging, determining the progressive
degeneration and pathologic alteration of this particular
tissue [16]. Morphological changes include dehydratation
and tears of the AF, NP, and EPs [16]. Common molecular
changes are decreased cell viability and diﬀusion of nutrient
and proteoglycans synthesis, accumulation and increasing of
degradative enzymes and degraded matrix macromolecules,
and, ﬁnally, alteration in collagen distribution [16].
The anabolic function of various growth factors is
explained with the accumulation and synthesis of matrix
while cytokines demonstrated the opposite eﬀect. They
promote catabolism and inhibit synthesis of IVD matrix.
Several inﬂammatory mediators have been found in
degenerated IVDs, but the real pathologic role of these
mediators is unknown or not clearly deﬁned. Nitric oxide
(NO), interleukin-6 (IL-6), prostaglandin E2 (PGE2), TNF-
alpha, ﬁbronectin, and matrix metalloproteinases (MMPs)
a r es o m eo ft h es e v e r a lm e d i a t o r si d e n t i ﬁ e d[ 16–20]. IL-
6, NO, and PGE2 have been proposed to be the inhibitory
factors of proteoglycan synthesis. These factors are recruited
into action by interleukin-1 (IL-1), which also plays a
role in the direct degradation of the proteoglycan matrix.
This process of direct breakdown by IL-1 is thought to be
mediated by a family of enzymes known as MMPs. IL-1
likely plays a major role in the cascade of inﬂammatory
mediators, but the nature of that role is not well deﬁned
[21], suggesting that the identiﬁcation of all mediators that
promote degradation of the IVD or accumulation of matrix
should be investigated to explore new therapy strategies.
3. Biological TherapyStrategies
Therapeutic strategies under investigation for the biological
treatment of IVD degeneration include the use of cellular
components (mesenchymal stem cells, chondrocytes, disc
allograft, culture expanded, disc cells, etc.), molecules inﬂu-
encing disc-cell metabolism and phenotype and matrix-
derivatives [22, 23]. The rationale of the biological strategies
for arresting and preventing IVD degeneration is linked with
the possibility to improve the accumulation of ECM by
promoting its synthesis and/or inhibiting its degradation.
This is also connected with IVD biological properties:
cells of the AF and NP respond to a diﬀerent number
of cytokines. In fact, IVD degeneration is associated with
reduced cellularity, and restoration may be aided by treat-
ments that protect against cell death and apoptosis, or
promote mitosis.
Several growth factors, including bone morphogenetic
protein-2 (BMP-2), BMP-7 (also known as osteogenic
protein-1 [OP-1; Stryker, Kalamazoo, Michigan]), growth
and diﬀerentiation factor-5 (GDF-5), transforming growth
factor-β (TGF-β), and insulin-like growth factor-1 (IGF-1)
stimulate matrix production while interleukin-1 (IL-1) and
tumor necrosis factor (TNF) inhibit the synthesis of matrix
and enhance its catabolism.
3.1. Enzymatic and Nonenzymatic Mechanisms. Other target
candidates of therapy include enzymatic and nonenzymatic
mechanisms involved in reabsorbing and degrading the
IVD matrix. Various types of proteinases, such as matrix
metalloproteinases, cathepsins, and members of the ADAM
(a disintegrin and metalloprotease) family, are implicated in
IVD matrix degradation. Nonenzymic mechanisms involv-
ing molecules such as nitric oxide, peroxynitrite, and super-
oxide are also candidates, but the extent to which they
are restrained by the anoxic environment of the IVD is
unknown.Mostoftheseexperimentalsolutionshavesomein
vitro data, but only few studies have been extended from in
vitro observation to an animal model of IVD degeneration,
especially to large animals models that can be compared to
human IVD disease.
In addition, as several animals were used to study IVD
degeneration,includingchemicalandnonchemicalstrategies
to simulate IVD degeneration in vitro and in vivo, there is
no agreement on which model best simulates human IVD
degeneration.
3.2. Growth Factors. Growth factors (GFs) are fundamental
components for the biological homeostasis of the IVD
tissues, and are also fundamental for the development of
the spine. Several GFs have been found in degenerated and
normal IVD tissues, suggesting that IVD cells are capable
of expressing and producing GF and to respond to GFs
stimulation, changing their phenotype according to the
GFs present at a given time. Indeed, stimulation of matrix
synthesis by GFs alters the tissue homeostasis and changes
cellular metabolism to the anabolic state [2].
The most studied GFs in IVD degeneration are TGF-
b1-3 [24–26], IGF-1 [25, 27], basic ﬁbroblast growth factor
(bFGF) [28–30], growth diﬀerentiation factor-5 (GDF-5)
[31], platelet derived growth factor (PDGF) [32], BMP-2
[33], and BMP-4 [31, 33].
TGF-b1 and -b2 and bFGF were found to be expressed
in human degenerated IVDs [34]. TGF-b receptor II (TGF-
bRII), FGF receptor 3, and BMPRII were also found to be
present to a similar extent in both human diseased and
normal tissues [35].
The rationale for the use of GFs for prevention and
treatment of IVD degeneration lies in their capacity to
regulate phenotype of IVD cells, promoting an anabolic state
with enhanced matrix synthesis and accumulation.
3.3. In Vitro Studies on Growth Factors Application. Cell
proliferation and matrix synthesis and metabolism can be
upregulated when exogenous growth factors are applied to
tissue or cell cultures.
In1991,Thompsonetal.[36]ﬁrstdescribedtheeﬀectsof
various growth factors, including TGF-b, epidermal growth
factor (EGF), and bFGF on proteoglycan (PG) synthesis by
IVD cells. TGF-b1 was expressed frequently by NP cells and
occasionally by AF cells when they were spatially associatedStem Cells International 3
withﬁbronectin-synthesizing cells[37]. Moreover, in human
three-dimensional IVD cell cultures, TGFb stimulates cell
proliferationofannuluscellsafterfourdaysofexposure[38].
IGF-1 stimulated PG synthesis by bovine NP cells in serum-
free conditions in a dose-dependent manner [27].
In addition, IGF-1 and PDGF signiﬁcantly reduced the
percentage of apoptotic AF cells induced by serum depletion
in culture [39] while, in rabbit IVD cells, the responsiveness
of IVD cells to IGF-1 and TGF-b decreases with increasing
age [40]. Melrose et al. [29] showed that, in monolayer
cultures of rat AF cells, recombinant human BMP-2 (10–
1000ng/mL) increased cell proliferation, mRNA expression
of collagen type II, aggrecan, osteocalcin, and SOX9 and
PG synthesis Yoon et al. [41]. Another study reported that
BMP-2 signiﬁcantly increased the expression of aggrecan,
collagen type II, TGFb1, and BMP-7 mRNA, and, on
the other hand, downregulated versican gene expression
[40]. BMP-2 increases and facilitates the expression of the
chondrogenic phenotype by human IVD cells. rhBMP-2
increased PG synthesis and upregulated the expression of
aggrecan, collagen type I, and collagen type II mRNA,
compared to untreated control levels [42]. In rabbit IVD
cells, BMP-7, also known as osteogenic protein-1 (OP-1)
strongly stimulates the production and formation of PG and
collagen and slightly aﬀected cell proliferation [43].
In both NP and AF cells, recombinant human OP-1
(rhOP-1)stimulatedtheproductionandaccumulationofPG
and collagen in a dose-dependent manner (50–200ng/mL)
in the presence of 10% fetal bovine serum (FBS). Data from
previous cadaveric studies indicated that the capacity of NP
and AF cells to synthesize PGs decreases with age [44].
However, OP-1 signiﬁcantly stimulated PG synthesis
in all fetal, adult, and old bovine NP and AF cells [45],
suggesting that the IVD cells in older animals are responsive
t oG F s ,s u c ha sO P - 1 .
OP-1 (100–200ng/mL) improved the in vitro production
of PGs by human NP and AF cells cultured in alginate beads,
especially in the presence of 10% FBS [43].
OP-1 also enhanced the accumulation of PGs in the
matrix, and AF cells, which are more ﬁbrochondrocytic,
strongly responded to OP-1: OP-1 might be beneﬁcial not
only for nucleus repair but for anular repair too [43].
Takegami et al. treated the IVD cells cultured in alginate
beadswithIL -1[46]orchondroitinaseABC(C-ABC)[47]t o
damage or to deplete the PG-rich matrices, simulating IVD
degeneration.AfterdepletionoftheECMfollowingexposure
of IVD cells to IL-1, OP-1 was found to be eﬀective in the
replenishment of a matrix rich in PG and collagen.
OP-1 treatment increased DNA content, and collagen
and PG synthesis and accumulation in both early and
advanced stages of IVD degeneration, but to a greater and
successful extent in early stages of IVD degeneration [48].
The use of growth factors may be suitable in the early rather
than in the late stages of IVD degeneration.
Growth and diﬀerentiation factor-5 (GDF-5), another
member of the BMP family, was ﬁrstly described in the
literature for its capacity to be a crucial factor responsible
for skeletal alterations in brachypodism mice [49]. GDF-5-
deﬁcient mice showed IVD degradation and degeneration,
and with a low T2-weighted signal intensity and loss
of normal lamellar architecture of the AF at MRO, and
disorganized NP with a decreased PG content [50]. GDF-5
stimulatedcollagentypeIIandaggrecanexpressioninmouse
IVD cells [50].
Some studies also indicated that rhGDF-5 promoted
matrix synthesis/accumulation and cell proliferation by both
bovine NP and AF cells, with a better response by NP cells
compared with AF cells [45].
Platelet-rich plasma (PRP) is a plasma fraction that
contains multiple growth factors concentrated at high levels
[48, 51, 52], and is produced by the centrifugation of the
blood [53, 54]. PRP, administered in porcine cells cultured in
alginate beads, is an eﬀective stimulator of cell proliferation
and PG and collagen synthesis, as well as PG production and
accumulation, by both AF and NP cells [55].
The combination of autologous IL-1 receptor antago-
nist (IL-1ra)/IGF-1/PDGF proteins reduced the percentage
of cellular apoptosis and the production of biochemical
markers of IVD degeneration, such as IL-1 and IL-6. These
results suggested the possibility of new strategies, using an
autologous protein mixture, containing IL-1ra/IGF-1/PDGF,
for the treatment of degenerative IVD disease [56].
3.4. In Vivo Studies on Growth Factors Application. The ﬁrst
study on GF injection into the IVD was reported by Walsh et
al. [57] in the mouse caudal IVD degeneration model. In this
study, IVD degeneration was induced by static compression
[57]. A single injection of GDF-5, but not that of IGF-1,
TGF-b, or bFGF, promoted IVD regeneration while multiple
injections (four injections, one per week) of TGF-b showed
a stimulatory eﬀect. Finally, multiple injections of IGF-1,
GDF-5, and bFGF did not show a signiﬁcant enhancement
of their primary eﬀect [57]. A combined approach with
a mechanical or cell-based device or a sustained delivery
system was required to obtain a beneﬁcial therapeutic eﬀect.
An et al. [58]p e r f o r m e da nin vivo experiment using
the normal rabbit IVD and a single injection of OP-1 (2
lg per disc) to test the eﬃciency of OP-1 for the treatment
of degenerative IVD disease. A single in vivo intradiscal
injection of OP-1 resulted in increased PG content of the NP
and disc height (15%) [58].
Additionally, the same authors conducted a study of
radiographic and magnetic resonance imaging ﬁndings in
the rabbit IVD after injection of OP-1 into the NP in the
anular-puncturediscdegenerationmodel. IVDdegeneration
was induced by anular puncture in two noncontiguous
discs with an 18G needle [59]. Four weeks after the
anular puncture, either 5% lactose or OP-1 was injected
into the center of the NP. Six weeks after the intradiscal
administration of OP-1, an increase of signal intensity of
NP in T2-MRI associated with restoration of disc height
were observed and sustained along the entire experimental
period, up to 24 weeks [60]. Histologically, the degeneration
grades of the punctured discs in the OP-1-injected group
were signiﬁcantly lower than those of the lactose-injected
group. Biochemically, the PG content of the AF and NP was
higher in the OP-1-injected discs than in the control group
treated with lactose injection. This study demonstrated the4 Stem Cells International
feasibility of restoring degenerative rabbit discs by a single
injection of OP-1 into the NP. In addition, the restoration of
discheight,whichusuallybeganat6weeks,wassustainedfor
up to 24 weeks.
Chondroitinase ABC (C-ABC) chemonucleolysis was
used by several authors to simulate an animal model of disc
degeneration in the goat disc [61, 62] and in the rat tail [63,
64], and was used also as an alternative degradation method
to chymopapain treatment. The eﬀect of OP-1 has been
also validated in a chondroitinase-induced chemonucleolysis
model in rabbits. These data suggest the feasibility of OP-
1 administration in patients with IVD degeneration who
had previously received chemonucleolysis that resulted in
eﬀective loss of disc height.
Moreover, regarding the stimulatory capacity on matrix
accumulationand/orsynthesisinducedbyOP-1,aninjection
of rhOP-1 performed following chemonucleolysis with C-
ABC may be a successful strategy to oppose the degradative
eﬀects of the enzyme and to induce the healing of the IVD
structure. In adolescent rabbits, C-ABC (10mU) was ﬁrst
injected into IVDs to induce chemonucleolytic eﬀects [65].
Four weeks after the injection of C-ABC, OP-1 (100μg/disc)
or vehicle was injected and the disc height was measured for
up to 12 weeks after the OP-1 treatment. The disc height
after the injection of C-ABC was signiﬁcantly decreased
(approximately 34%), and this ﬁnding was statistically
signiﬁcant. The injection of OP-1 induced a recovery of the
disc height towards normal within 4 weeks after the rhOP-1
injection, graduallyapproachingthecontrollevelby6weeks.
This change was sustained for up to 16 weeks. The results of
an injection of rhGDF-5 in the rabbit anular-puncture IVD
degeneration model also conﬁrmed the eﬃcacy of injection
ofgrowthaddiﬀerentiationfactor.TheIVDswerepunctured
by a needle as described in the OP-1 experiment to produce
IVD degeneration. Four weeks after, the rabbits received a
single injection of rhGDF-5 (10ng, 1μg, and 100μg) or
phosphate buﬀered saline (PBS) and were then followed
up for 16 weeks for disc height with MRI ﬁndings, and
histological grades with biopsy. The injection of rhGDF-5
resultedinareplacementofIVDheightandimprovementsin
MRI ﬁndings and histological grading scores with statistical
signiﬁcance (P<0.05–0.001) [45].
In 2-year-old rabbits, the intradiscal injection of rhGDF-
5 induced a signiﬁcant recovery of disc height during a 12-
week observation period [45] .T h er e s p o n s et ot h eG D F - 5
injection was faster than that seen in the adolescent rabbits.
Two weeks after the injection, the percent disc height index
(%DHI) in the rhGDF-5-injected discs was signiﬁcantly
higher than that in the PBS-injected discs. By 8 weeks
afterinjection, the rhGDF-5-injected discs reached the DHI
level of the nonpunctured control discs. At 12 weeks after
the injection, at MRI the signal intensity in the NP of the
rhGDF-5-injected discs was signiﬁcantly higher than that
of the PBS-injected discs. Biomechanically, the viscous and
elastic moduli of the IVDs in the rhGDF-5-injected discs
weresigniﬁcantlyhigherthanthoseinthePBS-injecteddiscs.
These results indicated the eﬀectiveness of an injection of
rhGDF-5 in restoring the degenerative disc in the 2-year-old
rabbit anular-puncture disc degeneration model, despite the
concern that age-related changes in cell activity might aﬀect
the eﬃcacy of growth factor injection therapy [45].
In addition, normal discs from the adolescent rabbits (5-
6 months) used in these studies still have a large number
of notochordal cells [42, 66]. Notochordal cells in the NP
were substituted with ﬁbrochondrocytes after the needle
puncture, and this diﬀerence in cell populations needs to be
taken in account for preclinical information in futurehuman
clinical trials.
An age-related decrease in PG and water content and
increased degenerative signs in sagittal MRI scans was found
in a cross-sectional study using 1–4-year-old rabbits [67].
One can speculate that mature or older rabbits also show less
diﬀusion through the EP because of decreased vascularity,
compared to adolescent animals. Therefore, repair of the
degenerated IVD may be age-dependent, and mature rabbits
may not be able to restore disc structure by growth factor
injection as demonstrated in the young animals described
above.
Several possible mechanisms for the long-term eﬀects
of growth factor injection warrant further investigation.
First, the half-life of an injected protein in discs has been
considered to be short, in the order of minutes [68]. Finally,
the biological and metabolic changes found in the cells
following a single injection of a growth factor might be
sustained and thus could induce long-term changes in disc
structure. However, the results from the use of other GFs
have shown some discrepancies in the studies found in the
literature.
Huang et al. injected saline (100μL) or BMP-2 alone
or BMP-2 with coral grafts, after a full-thickness anular
tear, in rabbit discs [69]. Radiographs after the treatments
revealed that degenerative changes were more frequent and
severe in the animals treated with rhBMP-2 with or without
the use of coral. At histology, rhBMP-2 promoted ﬁbroblast
proliferation and hypervascularity of the intervertebral disc
after an anular tear. These discrepancies may result from the
factthattheannulartearmodelsimulatesanacutecondition,
andtheapplicationofBMP-2wasperformedduringanacute
phase.
Nagae et al. recently reported ﬁndings on the eﬀects
of PRP in the rabbit IVD following nucleotomy [70].
PRP was injected into the NP of degenerated IVDs after
impregnation into gelatin hydrogel microspheres to produce
a slow condition to release the biological factors found in
PRP while other IVDs received PRP or PBS without impreg-
nation into gelatine hydrogel microspheres. Gelatin hydrogel
immobilize PRP growth factors physicochemically, allowing
to release them in a sustained manner with the subsequent
degradation of the microspheres. The progression of IVD
degenerationwassuppressedinthegroupinjectedwithPRP-
microspheres, compared to the PBS and PRP only groups.
This ﬁnding conﬁrmed Walsh’s indication [57] about the
necessity to ﬁnd a sustained delivery system for growth
factor injection, which must be speciﬁc and dependent on
the kind of growth factor injected. In addition, when the
defect in the NP is associated with its pathogenesis, such
as postdiscectomy, the use of such a scaﬀold or delivery
system may provide a beneﬁt to patents. Some authors foundStem Cells International 5
that the adenovirus is an eﬀective vehicle for gene delivery
with rapid and prolonged expression of target protein and
resulting improvement in markers of disc degeneration. Ad-
GDF5 or DMP-7 gene therapy could restore the functions
of injured discs and has the potential to be an eﬀective
treatment [71, 72].
3.5.LimitationsofGrowthFactorInjectionTherapy. Thereare
several limitations of GF injection therapy for IVD degener-
ation. The cell number is substantially decreased in degener-
ated discs, especially in the advanced stages [24]. Therefore,
a reduced number of cells are present in IVD degenerated
IVDs, and only few of them are able to respond to GFs
stimulation. Some authors reported speciﬁcs methods for
prevention of this cellular deﬁcit, such as the association of
GFs injection and transplantation of healthy functional cells
(i.e., autologous NP cells) [73–76]. Other authors utilized
GFs and cells treated with transfection of a therapeutic gene,
to obtain the combination eﬀect on the implementation of
cells number and the gene therapeutic eﬀect [77].
Nutrition is another important factor linked with the
pathogenesisofdiscdegenerativedisease[78].TheIVDisthe
biggest avascular tissue in the human body, and its survival
depends on nutrients diﬀusion from the vertebral bodies
through the EPs. In the degenerated IVD, the sclerosis of
the EP did not guarantee a correct diﬀusion of nutrients,
and this condition worsens with a substantial alteration
of the IVD tissues and with the worsening of IVD tissues
condition and onset of an irreversible state. The increased
demand for energy resulting from the stimulation by GFs
or by cell supplementation may aﬀect cell viability under
those conditions where nutrient transport is compromised.
Further investigations of the optimal environment for GF
stimulation should be pursued.
Age-dependent limitations emerged in the therapy of
IVD degeneration with GFs, especially concerning the pos-
sibility of the few cells present in the degenerated IVD, to
respond to GFs stimulation [15]. Because of the emerging
trend to treat disc degeneration in adults or older individuals
by local injection of growth factors, degeneration stage-
related characteristics and age-related ﬁndings, changes, and
diﬀerencesintheresponsetogrowthfactors,areofparticular
interest for future studies [79].
Often, a delayed response in the recovery of disc height
by IVD cells in vivo after administration of GFs is observed.
Themechanismofthisphenomenonremainsundetermined.
However, it is possible that the half-life of the injected GF
may be longer than expected; the capacity to respond to a
single administration of a growth factor can continue over a
long period of time. Finally, the stimulation by growth factor
maydetermineacascadeofevents,eventuallyresultinginthe
healing and recovery of disc height.
The in vitro and in vivo evidence described above
supports the hypothesis that the direct injection of GFs
into the NP or the AF may be clinically eﬀective as a new
therapeutic strategy for the prevention and treatment of IVD
degeneration.
The acceleration of the biological repair process by the
stimulation of the cellular anabolic capacity will determine
a new category of therapy, where no active treatment
currently exists, between conservative therapies and more
aggressive therapies such as surgical intervention of vertebral
arthrodesis or disc replacement.
4. AnticatabolicAgents
The inhibition of degradative molecules can be important
to prevent IVD degeneration. Anticatabolics prevent matrix
degradation by inhibiting particular enzymes within the disc
[20]. Several families of enzymes are capable of breaking
down the various molecular components of IVD matrix,
including cathepsins, aggrecanases, and MMPs [18, 80].
MMPs play an important role in the normal turnover of
matrix molecules, but they have also been linked with
degradationofcollagen,aggrecan,versican,andlinkproteins
found in the degenerated disc [80]. The main members
of the MMP family are collagenase (MMPs 1, 8, and 13),
gelatinase (MMPs 2 and 9), and stromelysin (MMP 3).
Collagenase and gelatinase cooperate in the breakdown and
degradationofcollagencontainedintheAF.Stromelysinacts
prevalently in the NP, and it is involved in the breakdown
of the core protein of proteoglycans. Stromelysin is able
to access the proteolytic cleavage sites, saving hyaluronate-
binding regions, degraded proteoglycan aggregates, and
glycosaminoglycan fragments as breakdown products [18,
80–82]. Moreover, TNF-alpha-stimulated gene-6 (TSG-6),
found in herniated disks, is another potential therapeutic
molecule with anti-inﬂammatory properties which blocks
destructive proteinases [83].
In addition, following the current information of syn-
thesis and degradation of IVD tissues, the rate of disc-
matrix biological metabolism may also be important. For
example, the overall rate of disc metabolism in discs from
younger individuals is higher than in discs from older
individuals. Moreover, in discs from older individuals,
aging promotes the accumulation of degraded products in
comparison to the newly synthesized molecules, inducing
a catabolic permanent state. This disparity of ﬁndings is
evident for aggrecans when looking at aged IVDs. Aggrecan
and versican degradation is usually performed by another
family of metalloproteinases, the ADAMs. Two members of
this family (ADAM-TS4 and TS5) show a particular aﬃnity
for aggrecan, and are also called aggrecanases [16].
Given the degradative properties of MMPs, more atten-
tion should be given to inhibiting MMPs methods, to
try to slow or arrest IVD degeneration. MMP activity
is physiologically inhibited by tissue inhibitors of MMPs
(TIMPs) [82, 84]. Wallach et al. [84] successfully delivered
an anticatabolic gene TIMP-I, using an adenoviral vector,
into the cells from degenerated IVD. They also demonstrated
an increased expression of TIMP-1 in disc cells and also
an increase in the proteoglycans contennt. In other studies,
TIMP inhibited the breakdown of proteoglycans, such as
aggrecan, and may be a potential molecular therapy strategy
for the management of IVD degeneration [85, 86].
Finally, cytokines such as TNF-alpha and IL-1 may have
critical roles in disc metabolism and the pathogenesis of IVD
degeneration. Several inﬂammatory cytokine antagonists,6 Stem Cells International
including IL-1 antagonists and TNF-a antagonists, have also
been studied with in vitro and in vivo [87].
IL-1Ra and Inﬂiximab, which can reduce IL-1 and TNF-
alpha blood levels, respectively, may be also useful as an
alternative pharmacological therapy for the IVD degenera-
tion [88–90]. In addition, recent studies demonstrated the
possibility to reduce IVD degeneration by the inhibition of
TNF-alpha molecules using etanercept. Perispinal etanercept
injection may be useful for both acute and chronic disc-
related pain, especially in patients with chronic refractory
disc-related pain [91]. Recently, Horii et al. [92]c o n d u c t e d
an interesting experiment using etanercept in the dorsal
root ganglia (DRG) of rats. The neurotracer FluoroGold
was applied to the surfaces of L4/5 IVD to label their
innervating DRG neurons (n = 30). Of 30 rats, 10 were in a
nonpunctured disc sham surgery control group whereas the
other 20 were in experimental groups in which intervertebral
IVDs werepunctured witha 23G needle. Etanercept or saline
was applied into the punctured discs (n = 10 each treat-
m e n t ) .A f t e r1 4d a y so fs u r g e r y ,D R G sf r o mL 1t oL 6w e r e
harvested, sectioned, and immunostained for CGRP. The
proportion of FluoroGold-labeled CGRP-immunoreactive
DRG neurons was evaluated in all groups. CGRP was
upregulated in DRG neurons innervating damaged discs.
However, direct intradiscal application of etanercept imme-
diately after disc puncture suppressed CGRP expression in
DRG neurons innervating injured discs. In a double-blind,
placebo-controlled, dose-response pilot study, Cohen et al.
[93] reported that no serious side eﬀects were observed
after a single low-dose intradiscal injection of etanercept.
The same conclusions were reached in a blind randomized
controlled trial using etanercept injection for the treatment
of sciatica [56]. The study [56] did not show beneﬁts after
the use of etanercept over placebo in the pharmacologic
treatment of sciatica.
Finally, CPA-926 can be used in the IVD degeneration
for its anti-inﬂammatory and anti-tumorigenic properties.
Following oral administration of CPA-926, histological and
radiographic ﬁndings on an annulotomy model of IVD
degeneration in rabbits showed a delay of the onset of
disc-height loss [94]. Further research into anticatabolic
molecules should be performed.
4.1. Limitations of Anticatabolic Therapy. The most impor-
tant limitation of this approach is linked to the chronic
nature of the IVD degeneration disorder. IVD degeneration
is a long-term problem, occurring gradually and worsening
with aging. The normal in vivo half-life found for these
therapeutic molecules is on the order of only few minutes,
and this suggests that the eﬀects of these molecules will not
last for signiﬁcant periods of time. Therefore, if anticatabolic
therapy can be eﬀective in the long term, repeat or contin-
uous infusions need to be performed, limiting the clinical
utility of direct molecular-based therapies [95–107].
5. Summary
The normal intervertebral disc is a complex structure able to
dissipate loads and permit multiaxial motion of the spine.
The homeostasis of the IVD tissues is maintained trough
a ﬁne balance between matrix synthesis and degradation,
which determines biological changes and microstructural
modiﬁcation and consequent organization. IVD degener-
ation leads to the alteration and loss of function of the
IVD tissues, disrupting the well-deﬁned organization of IVD
structures and also of the IVD biomechanical balance. The
major problem of IVD degeneration is the progressive loss
of proteoglycan and water in the NP, followed by matrix
degeneration and presence of catabolic molecules in the
IVD tissues [108–114]. The restoration of the proteoglycans
content in the NP, such as the inhibition of the molecules
involved in the matrix degeneration including, can be a
possible solution for management of IVD degeneration.
Several biological molecules can be potentially useful and
eﬀective in IVD repair. GFs and anticatabolic molecules are
possible ﬁelds of study and intervention. Many of these
molecules have been investigated in vitro, and several have
been used in animal model of IVD degeneration. The next
step of research should be performed with animal model of
IVD degeneration to better simulate the human condition.
In addition, the use of GFs and of anticatabolic molecules
demonstrated important limitations for future preclinical
studies [6, 7, 20, 53, 114–163].
Major drawbacks in the ﬁeld include the poor delivery
methods, the rapid eﬀect and formulation of therapeutic
molecules, and the lower percentage of cells able to respond
to GFs and anticatabolic stimulation found in degenerated
IVD tissues. GFs injection can be useful in IVD degeneration
if administered in the early phase of the disease while the
reduced number of cells found in IVD degenerated tissues
can be a major problem [95, 104, 105, 164–188]. Only few
cells are present in IVD degenerated tissues and are able to
respond to GFs stimulation. Anticatabolic molecules show a
very short-term eﬀect and the in vivo half-life found of these
therapeutic molecules is on the order of only few minutes
suggesting that the eﬀects of these molecules will not last
for signiﬁcant periods of time. Future research should focus
on biological therapy research for the treatment of IVD
degeneration.
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